Market Overview - U.S. stock futures declined on Wednesday following a lower close on Tuesday, with major benchmark indices showing a downward trend [1] - The Consumer Price Index (CPI) rose 2.7% year over year in December, matching previous readings and economists' estimates, while core CPI was slightly below expectations at 2.6% [1] Economic Indicators - The 10-year Treasury bond yielded 4.17%, and the two-year bond yielded 3.52%, indicating investor sentiment towards interest rates [2] - The CME Group's FedWatch tool indicates a 97.2% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stock Performance - Major indices showed the following performances: Dow Jones -0.15%, S&P 500 -0.16%, Nasdaq 100 -0.16%, Russell 2000 +0.14% [3] - SPDR S&P 500 ETF Trust (NYSE:SPY) was down 0.15% at $692.73, while Invesco QQQ Trust ETF (NASDAQ:QQQ) declined 0.20% to $625.00 in premarket trading [3] Company Focus - Wells Fargo & Co. (NYSE:WFC) was down 0.81% in premarket trading, with expected quarterly earnings of $1.67 per share on revenue of $21.65 billion [7] - BP PLC (NYSE:BP) dropped 1.84% after announcing potential writedowns of up to $5 billion in its energy transition businesses [7] - WeRide Inc. ADR (NASDAQ:WRD) rose 1.59% after launching the Robotaxi Mini Program "WeRide Go" on Tencent WeChat [7] Analyst Insights - Professor Jeremy Siegel anticipates a strong 2026 driven by productivity growth, with a surprising fourth-quarter GDP growth estimate of 5.4% [10] - Siegel suggests a shift in stock market leadership away from mega-cap technology stocks, predicting double-digit returns from small-cap stocks and non-tech cyclicals [11] Upcoming Economic Data - Delayed reports on U.S. retail sales and producer price index are scheduled for release at 8:30 a.m. ET [14] - Additional economic data, including business inventories and existing home sales, will be released at 10:00 a.m. ET [14] Commodities and Global Markets - Crude oil futures fell by 0.98% to around $60.57 per barrel, while gold prices rose by 0.93% to approximately $4,629.12 per ounce [16] - Bitcoin traded 3.32% higher at $94,969.36 per coin [16] Global Market Performance - Asian markets closed mixed, with India's Nifty 50 and China's CSI 300 indices falling, while Australia's ASX 200, Japan's Nikkei 225, Hong Kong's Hang Seng, and South Korea's Kospi indices rose [17]

Core Viewpoint - U.S. stock futures are trading lower, with several companies expected to report quarterly earnings, drawing investor attention [1] Company Earnings Expectations - Bank of America Corp (NYSE:BAC) is anticipated to report quarterly earnings of 96 cents per share on revenue of $27.87 billion, with shares slipping 0.1% to $54.51 in after-hours trading [1] - Citigroup Inc (NYSE:C) is expected to post quarterly earnings of $1.68 per share on revenue of $20.53 billion, with shares falling 0.1% to $116.15 in after-hours trading [1] - Wells Fargo & Co (NYSE:WFC) is projected to report quarterly earnings of $1.67 per share on revenue of $21.65 billion, with shares decreasing 0.2% to $93.38 in after-hours trading [1] Company Updates - TG Therapeutics, Inc. (NASDAQ:TGTX) provided preliminary fourth quarter revenue estimates, expecting U.S. net product revenue of approximately $182 million for Q4 and $594 million for the full year of 2025, with total global revenue for 2025 expected to be around $616 million [1] - Gelteq Ltd. (NASDAQ:GELS) reported positive preclinical results for its cannabinoid oral gel delivery platform, leading to a significant share price increase of 69.3% to $1.41 in after-hours trading [1]

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]

Company Overview - TG Therapeutics was founded in 2012, focusing on B-cell-mediated diseases, including autoimmune diseases, neuroinflammatory conditions, and cancer [3] - The company is primarily focused on multiple sclerosis (MS) and has one approved drug, BRIUMVI, which is approaching blockbuster status [3] Product Information - BRIUMVI is an anti-CD20 monoclonal antibody that was approved in late December 2022 and launched in January 2023 [4] - The drug is not only available in the U.S. but has also been launched globally [4] Clinical Development - TG Therapeutics has two pivotal trials ongoing to expand the utilization and total addressable market for BRIUMVI [3] - The company has three additional programs under development [3]

TG Therapeutics Conference Call Summary Company Overview - **Company**: TG Therapeutics (NasdaqCM:TGTX) - **Focus**: B-cell mediated diseases, primarily multiple sclerosis (MS) - **Approved Drug**: Briumvi, an anti-CD20 monoclonal antibody for MS, launched in January 2023 - **Market Presence**: Available in 16 countries, with over 20,000 patients prescribed Briumvi to date [2][3] Core Market Insights - **Anti-CD20 Market**: Represents approximately $10 billion in sales, with Briumvi capturing about 20% of the total market share and one-third of the healthcare provider-administered segment [4][6] - **Growth Potential**: The anti-CD20 class holds a 50% market share in new prescriptions, indicating room for growth [4][5] Financial Performance - **2026 Revenue**: Total global revenues of $616 million, with U.S. net revenue of $594 million, reflecting a 90% year-over-year growth [7][9] - **Cumulative Revenue**: Exceeded $1 billion in cumulative net sales within less than three years of launch [6][7] - **Forecast for 2026**: Targeting $875 million to $900 million in global net revenue, primarily from U.S. sales [27][28] Product Development and Future Plans - **Upcoming Trials**: - Enhanced IV protocol aimed at consolidating dosing to simplify onboarding, with top-line data expected mid-2026 [18][19] - Development of a self-administered subcutaneous (subcu) version of Briumvi, with a pivotal study currently over 50% enrolled and a target launch in 2028 [20][21] - **Expansion Beyond MS**: Plans to explore additional indications for Briumvi, including myasthenia gravis (MG) and neuromyelitis optica (NMO) [25][26] Competitive Landscape - **Market Positioning**: Briumvi is positioned as the lowest-priced branded MS treatment, enhancing its appeal in a competitive market [12][13] - **Sales Force Strategy**: Plans to increase the sales force by 10%-20% to target high-opportunity healthcare providers [14][34] R&D and Pipeline - **Azer-cel**: An allogeneic off-the-shelf CD19 CAR-T product in development for progressive MS, with data expected in 2026 [25][44] - **Long-term Opportunities**: Patents extending into the mid-2040s, with ongoing evaluations for new indications and potential drug launches [31] Key Takeaways - **Market Dynamics**: Briumvi's growth trajectory is strong, with significant market share gains and a robust pipeline for future growth [30][31] - **Operational Efficiency**: The company maintains low operating expenses relative to revenue, indicating potential for profitability acceleration [31][29] - **Patient Engagement**: Emphasis on patient awareness campaigns to drive market share, recognizing the importance of shared decision-making in MS treatment [15][16] Conclusion - TG Therapeutics is well-positioned for continued growth in the MS market with Briumvi, supported by strategic product development and a focus on patient and healthcare provider engagement. The company anticipates significant revenue growth and operational efficiency in the coming years, with a strong pipeline of future products and indications.

Core Viewpoint - TG Therapeutics, Inc. has released optimistic preliminary revenue estimates for Q4 2025 and a positive outlook for 2026, leading to a rise in stock price [1][3]. Revenue Estimates - The company expects Briumvi U.S. net product revenue to be approximately $182 million for Q4 2025 and $594 million for the full year of 2025, with total global revenue for 2025 estimated at around $616 million [2]. - For 2026, TG Therapeutics is targeting total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of about $825 to 850 million [2]. Market Performance - Briumvi has shown strong commercial performance in 2025, indicating a significant market share capture since its launch, which positions TG Therapeutics for long-term revenue growth and cash flow [3]. - Following the announcement, TG Therapeutics shares increased by 6.60%, reaching a price of $29.71 in extended trading [3].

BRIUMVI Market Position and Growth - BRIUMVI is the first and only anti-CD20 therapy for Relapsing forms of Multiple Sclerosis (RMS) delivered in a 1-hour infusion every 6 months after the starting dose[9, 21] - Anti-CD20s capture approximately 50% of the dynamic and overall Multiple Sclerosis (MS) market share, representing a ~$10 billion market in the U S today[12] - BRIUMVI has achieved significant uptake, with >97% of the top 200 MS centers using it and ~90% of high decile Healthcare Professionals (HCPs) prescribing it[16] - The company's goal is to become the 1 prescribed anti-CD20 in RMS based on dynamic market share[14] Financial Performance and Guidance - Cumulative BRIUMVI U S net revenue LTD is approximately $992 million[19] - BRIUMVI U S net revenue for Q4 2025 was approximately $182 million, and for FY 2025, it was approximately $594 million[19] - Total global revenue for FY 2025 was approximately $616 million, representing ~90% growth from FY 2024 to FY 2025 and ~20% growth from Q3 2025 to Q4 2025[19] - The company projects FY 2026 total global net revenue to be approximately $875-900 million, with U S net revenue of approximately $825-850 million[45] Pipeline Expansion and Future Launches - The company is developing a consolidated dosing schedule for IV BRIUMVI, with a target launch in 2027, pending top-line data from the ENHANCE pivotal study expected in mid-2026[27, 33] - A self-administered subcutaneous (SubQ) formulation of BRIUMVI is in development, with a target launch in 2028, pending top-line data expected by YE26/Q1 27[27, 38] - The SubQ formulation is expected to significantly increase the total addressable market by reaching a distinct patient segment, augmenting the current IV business[39, 41]

Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectivelyFull Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics), today announced prelimina ...

Company Overview - TG Therapeutics, Inc. is a fully integrated, commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [3] - BRIUMVI has also received approval from several regulatory agencies outside of the U.S. for treating adult patients with relapsing multiple sclerosis who have active disease defined by clinical or imaging features [3] Upcoming Events - Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 1:30 PM PST [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible after the event [2]

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible for both seasoned and novice investors [1] Mission and Community Engagement - The company aims to empower individuals financially by sharing its knowledge through Seeking Alpha, contributing analyses and informed perspectives [1] - Allka Research seeks to demystify investing, inspiring confidence in readers and fostering a community of informed investors [1] - The organization is dedicated to unraveling the complexities of the financial world, promoting wealth creation and discovery [1]